Guggenheim reiterated their buy rating on shares of Endo International plc – (NASDAQ:ENDP) in a research note issued to investors on Wednesday, Marketbeat reports. They currently have a $110.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Goldman Sachs reiterated a conviction-buy rating and issued a $84.00 price objective on shares of Endo International plc – in a report on Monday, October 26th. Mizuho started coverage on shares of Endo International plc – in a report on Thursday, October 8th. They issued a buy rating and a $82.00 price objective for the company. Canaccord Genuity reiterated a buy rating and issued a $104.00 price objective on shares of Endo International plc – in a report on Wednesday, September 30th. Zacks Investment Research raised shares of Endo International plc – from a hold rating to a strong-buy rating and set a $80.00 target price for the company in a research report on Thursday, October 1st. Finally, Leerink Swann cut their target price on shares of Endo International plc – from $96.00 to $74.00 and set an outperform rating for the company in a research report on Tuesday, September 29th. Nine investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $83.73.

Shares of Endo International plc – (NASDAQ:ENDP) traded down 5.37% during trading on Wednesday, reaching $54.95. The company’s stock had a trading volume of 6,549,082 shares. The company’s 50-day moving average price is $58.39 and its 200 day moving average price is $68.10. Endo International plc – has a 1-year low of $46.66 and a 1-year high of $96.58. The stock’s market capitalization is $12.44 billion.

Endo International plc – (NASDAQ:ENDP) last issued its quarterly earnings data on Thursday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.00 by $0.02. The business earned $746 million during the quarter, compared to the consensus estimate of $736.16 million. The company’s revenue for the quarter was up 14.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.15 earnings per share. Analysts anticipate that Endo International plc – will post $4.57 EPS for the current year.

In related news, EVP Susan Hall purchased 1,000 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The shares were acquired at an average cost of $55.35 per share, with a total value of $55,350.00. Following the completion of the purchase, the executive vice president now directly owns 7,515 shares of the company’s stock, valued at $415,955.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Silva Rajiv De purchased 9,006 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The shares were bought at an average cost of $55.52 per share, for a total transaction of $500,013.12. Following the completion of the purchase, the chief executive officer now directly owns 13,697 shares of the company’s stock, valued at $760,457.44. The disclosure for this purchase can be found here.

Other institutional investors have made changes to their positions in the company. Jennison Associates boosted its position in shares of Endo International plc – by 35.5% in the third quarter. Jennison Associates now owns 4,054,759 shares of the company’s stock worth $280,914,000 after buying an additional 1,062,201 shares during the last quarter. Cumberland Partners Ltd boosted its position in shares of Endo International plc – by 106.1% in the fourth quarter. Cumberland Partners Ltd now owns 363,435 shares of the company’s stock worth $22,249,000 after buying an additional 187,100 shares during the last quarter. Verde Servico Internacionais acquired a new position in shares of Endo International plc – during the fourth quarter worth about $19,005,000. Chevy Chase Trust Holdings boosted its position in shares of Endo International plc – by 0.6% in the fourth quarter. Chevy Chase Trust Holdings now owns 171,591 shares of the company’s stock worth $10,504,000 after buying an additional 1,088 shares during the last quarter. Finally, Rhenman & Partners Asset Management boosted its position in shares of Endo International plc – by 58.9% in the fourth quarter. Rhenman & Partners Asset Management now owns 116,000 shares of the company’s stock worth $7,102,000 after buying an additional 43,000 shares during the last quarter.

Endo International PLC, formerly Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In June 2014, the Company’s subsidiary, Endo Pharmaceuticals sold its pharmaceutical drug discovery platform to AsanaBioSciences, LLC. In June 2014, Asana BioSciences, LLC, an independent member of Amneal Alliance of Companies, acquired early-stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. In June 2014, Trendlines Group acquired intellectual property developed within the framework of an R&D agreement with the Company. In July 2014, it acquired Grupo Farmaceutico Somar.

12 Month Chart for NASDAQ:ENDP

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Endo International plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International plc - and related companies with MarketBeat.com's FREE daily email newsletter.